文献速递眼底病与葡萄膜炎

OCT增强的糖尿病视网膜病变筛查成本效益:50年Markov模型分析

Cost-effectiveness of OCT-enhanced screening for diabetic retinopathy: a 50-year Markov model analysis in type 2 diabetes.
PubMed 文献 · Br J Ophthalmol · 2026-05-05

研究用50年Markov模型模拟7729例2型糖尿病患者,比较CODMAP(联合两视野免散瞳眼底照相与OCT)与常规单视野免散瞳眼底照相的长期成本效益。

要点

  • CODMAP相比常规筛查增量成本效益比为124.25欧元/QALY。
  • 在3万欧元/QALY阈值下,CODMAP具有成本效益的概率为74.3%。
  • 成本与QALY变化是不确定性的主要驱动因素。

核心结论

  • CODMAP在西班牙背景下以有利的增量成本每QALY提供更大的长期健康收益。
  • 成本效益概率非确定性,需谨慎政策考量并关注本地基础设施、实施能力和成本结构。

研究设计与样本

  • 采用50年Markov模型模拟7729例2型糖尿病患者的糖尿病视网膜病变进展。
  • 模型含8个健康状态反映DR严重程度,每年累计状态特异性成本和QALY。
  • 分析采用西班牙国家卫生服务视角,应用3%年贴现率。

主要发现

  • 增量成本效益比(ICERROM)为124.25欧元/QALY。
  • 在3万欧元/QALY支付阈值下,成本效益概率为74.3%,情景分析中稳定在75.7%-78.8%。

关键数值与推荐

  • 支付阈值设定为3万欧元/QALY。

临床怎么用

  • 在西班牙公共卫生体系中,CODMAP可作为具有长期成本效益的DR筛查优化方案。
  • 实施时需结合本地基础设施、实施能力和成本结构进行政策评估。

局限性

  • 成本效益概率非确定性(74.3%),需谨慎解读。
  • 成本与QALY变化是不确定性的主要驱动因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetic retinopathy (DR) is a leading cause of preventable blindness among people with type 2 diabetes mellitus (T2DM). Early detection is essential to prevent vision-threatening complications. This study evaluated the long-term cost-effectiveness of CODMAP (Ophthalmologic Screening for Diabetes Mellitus in Primary Care (Cribado Oftalmológico en Diabetes Mellitus en Atención Primaria)), an optimised screening programme combining two-field non-mydriatic fundus photography (NMFP) and optical coherence tomography versus conventional single-field NMFP in a public healthcare setting. METHODS: A Markov model simulated DR progression over 50 years in a cohort of 7729 patients with T2DM. Eight health states reflected DR severity, with state-specific costs and quality-adjusted life years (QALYs) accrued annually. Analyses took the perspective of the Spanish National Health Service, applying a 3% annual discount rate. Incremental cost-effectiveness ratios, calculated as a ratio of means (ICERsROM), and net monetary benefits (NMBs) were estimated through 10 000 Monte Carlo simulations, at a €30 000 willingness-to-pay threshold. Deterministic and probabilistic sensitivity analyses, scenario analyses and bootstrap validation were performed. RESULTS: CODMAP accrued higher costs (€206.4 million vs €205.1 million) but more QALYs (128 691.7 vs 118 013.8), resulting in an ICERROM of €124.25/QALY. The probability of cost-effectiveness at €30 000/QALY was 74.3%, remaining stable in scenario analyses (75.7%-78.8%). Mean incremental NMB in the base case was €319.0 million. Cost and QALY variations were the main drivers of uncertainty. CONCLUSION: CODMAP offers greater long-term health gains at a favourable incremental cost per QALY in the Spanish context. However, the non-definitive probability of cost-effectiveness warrants cautious policy consideration, with attention to local infrastructure, implementation capacity and cost structures.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ruiz Bilbao S, Mas Casals A, Gómez Sánchez S, et al. Cost-effectiveness of OCT-enhanced screening for diabetic retinopathy: a 50-year Markov model analysis in type 2 diabetes. Br J Ophthalmol. 2026. PMID: 42086314. doi:10.1136/bjo-2025-327884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。